Vanda Pharmaceuticals
VNDA
110 hedge funds and large institutions have $431M invested in Vanda Pharmaceuticals in 2015 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 41 increasing their positions, 30 reducing their positions, and 22 closing their positions.
1,000% more call options, than puts
Call options by funds: $30.3M | Put options by funds: $2.76M
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
37% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 30
5% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 22
1% more funds holding
Funds holding: 109 → 110 (+1)
37% less capital invested
Capital invested by funds: $682M → $431M (-$251M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$45.5M |
| 2 |
AC
Armistice Capital
New York
|
+$17.6M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$15.7M |
| 4 |
JG
Jefferies Group
New York
|
+$9.38M |
| 5 |
State Street
Boston,
Massachusetts
|
+$9.13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$47.6M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$30.8M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$23.6M |
| 4 |
SCA
Signpost Capital Advisors
New York
|
-$11.9M |
| 5 |
WSA
Wall Street Associates
Lajolla,
California
|
-$9.39M |
VNDA Hedge Fund Activity: Q1 2015 in Review
110 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q1 2015, worth a combined $431M — down 37% from $682M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new VNDA positions and 22 closed out — a net gain of 1 holder — while 41 added to existing stakes and 30 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $45.5M. The largest seller was T. Rowe Price Associates, cutting an estimated $47.6M.
- 110 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q1 2015, up from 109 in Q4 2014.
- Funds reported $431M of Vanda Pharmaceuticals stock for Q1 2015, down 37% quarter-over-quarter.
- 23 funds opened new Vanda Pharmaceuticals positions in Q1 2015 and 22 closed out, a net change of +1 holder.
- The largest Vanda Pharmaceuticals buyer in Q1 2015 was Goldman Sachs, an estimated $45.5M added.
- The largest Vanda Pharmaceuticals seller in Q1 2015 was T. Rowe Price Associates, an estimated $47.6M sold.
Based on aggregated 13F filings for Q1 2015.